


DeepChek® Assay HPV messenger RNA (mRNA) Detection & Genotyping (RUO)

A Game Changer in Cervical Cancer Management



The Breakthrough: 5 Tests in 1

5 Tests in 1 – One Molecular Solution:

- HPV RNA Detection
- HPV Quantification
- HPV Genotyping
- Marker of Active Infection
- Precancer Lesions Determination

The Breakthrough

RNA-based NGS technology provides:

- Insight into viral activity (not just presence)
- Direct correlation with high-grade lesions (HSIL)
- Improved patient risk stratification


Why It Matters

Traditional screening:

- HPV DNA test → low predictive value
- Cytology → subjective, low sensitivity
- Multiple steps → costly & inefficient

Leads to unnecessary follow-ups and colposcopies

Gene expression balance serve as a molecular marker for different stages of HPV infection, with E6 and E7 genes associated with the cancerous state



Proprietary, ABL Diagnostics S.A. – 2026


For Research Use Only (RUO): not for use in diagnostic procedures, no claim or representation is intended to provide information for the diagnosis, prevention, or treatment of disease.

2/5




Overview


DeepChek® Assay HPV messenger RNA Genotyping employs a targeted-NGS methodology to generate RNA sequencing data from standard cervical swabs



From data to interpretation into a score



Scientific Workflow




Bioinformatics pipeline for analysis & interpretation

Results by patient

Copy	CSV	Excel	PDF	Print	Show 10 entries	Search:		
SampleName	Status	prediction	nb_HSK_genes	HPV_detected	HPV_covered	HPV_Not_HSIL	HPV_HSIL	max_score
1	Cytics-C6-01_S1_001	Multi-infected	HSIL	7	16,73,56	16	16	0.911968796519149
2	Cytics-C6-04_S4_001	Multi-infected	HSIL	13	16,18	16	16	0.699049010869685
3	Cytics-C6-06_S6_001	Mono-infected	HSIL	12	16			
4	Cytics-C6-11_S11_001	Mono-infected	HSIL	23	16			
5	Cytics-C6-13_S13_001	Multi-infected	HSIL	15	68,16			
6	Cytics-C6-21_S21_001	Multi-infected	HSIL	13	16,31			
7	Cytics-C6-22_S22_001	Multi-infected	HSIL	10	16,73			
8	Cytics-C6-24_S24_001	Multi-infected	HSIL	5	16,52			
9	Cytics-C6-29_S29_001	Multi-infected	HSIL	16	16,73			
10	Cytics-C6-30_S30_001	Multi-infected	HSIL	14	16,18			

Showing 1 to 10 of 95 entries



Analysis: Whole genome sequencing of HPV
 Technique: DeepChek® Genotyping Software (RUO) - HPV, ABL
 Sample: 121_Pasteur(02/02/2026)
 Patient: -
 Status: Not reviewed

GENOTYPING REPORT

Sample identification summary

Sample Information		Run Information	
Sample identification	121_Pasteur	Sequencing date	02/02/2026
Sample date	02/02/2026	Sequencing platform	MiSeq
Sample type	Missing Data	Assay lot ID	None
Software analysis details		Genotyping method	DeepChek® Assay Whole Genome HPV Genotyping
Application	HPV	Input files	121_1_S6_R1_001.fastq.gz 121_1_S6_R2_001.fastq.gz
Execution date	02/02/2026 15:21:59 CET+0100		
Runtime	0:11:11		
MicrobioChek® version	2.12.0		

Contact Information

Firstname	Jessica	Institution phone number	
Lastname	Arlaud	Institution fax number	
Job title		Signature	

Predictions

Status	HSK genes count	HPV detected	HPV covered	Prediction	Score
Multi-infected	5	16,52	16,52	HSIL	0.9771337108378997

Contacts & references

DeepChek® Assay HPV messenger RNA Genotyping (24 tests)..... 208A24

ABL Diagnostics S.A.
 72C Route de Thionville, 57140 WOIPPY, France

contact@abldiagnostics.com
<https://www.abldiagnostics.com/>



Proprietary, ABL Diagnostics S.A. – 2026

For Research Use Only (RUO): not for use in diagnostic procedures, no claim or representation is intended to provide information for the diagnosis, prevention, or treatment of disease.

